"Regulating Genome Engineering: The Role of Anti-CRISPR Proteins"

Scientists have developed off-switches for the Type I-C/Cas3 gene editor, a newer CRISPR platform with potential therapeutic use, to improve its safety. These off-switches, derived from anti-CRISPR proteins that bacteriophages have evolved to combat bacterial CRISPR immunity, can help mitigate off-target effects and increase the safety profile of CRISPR-based genome editing. The study, published in Molecular Cell, provides insights into the mechanisms of these off-switches, offering a potential path towards safer genome engineering.